The use of hydroxyurea, a medication that stimulates the production of non-sickling fetal hemoglobin, has resulted in a marked reduction in the number of vaso-occlusive events among young children with sickle cell anemia. However, it has not demonstrated a reduction in the risk of splenic sequestration crises, and primary prevention remains an unresolved goal.